Clinical Trial Update: Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apatinib combined with camrelizumab in recurrent or metastatic nasopharyngeal carcinoma after first-line treatment failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN